|
February 01, 2012
|
|
Taking Charge: A Blueprint for DePuy Hip Implant Recipients to Follow for Successful Recovery
|
|
While the FDA began receiving complaints regarding the failure of hip replacement devices manufactured by DePuy Orthopedics (a subsidiary of Johnson & Johnson) for some time, there was not a DePuy hip extensive recall on the device until August of 2010. Many feel the recall should have come much sooner and that the company knew there were issues with the implant for a significant period of time before they issued the recall. Many of the patients who have been implanted with a DePuy hip repla
|
|
Full Story
|
|
|
|
|
February 01, 2012
|
|
“Hip” Definitions: A Discussion of Medical Terms Every DePuy Hip Implant Recipient Should Know
|
|
July of 2003 saw the worldwide introduction of the metal-on-metal hip replacement by DePuy, although these devices were not used for hip replacement surgeries in the United States until 2005. Johnson & Johnson, the parent company of DePuy, pushed the approval of the hip implant device through the FDA under an expedited process known as the 510(k). This process allows many medical devices to skip rigorous clinical trials when the manufacturer can show the device is substantially equivalent to
|
|
Full Story
|
|
|
|
|
February 01, 2012
|
|
Johnson & Johnson Takes $3 Billion Dollar Fourth Quarter Charge
|
|
Johnson & Johnson, the parent company of DePuy Orthopedics recently took a fourth quarter charge of over $3 billion dollars related primarily to their voluntary recall artificial hip implants—the DePuy ASR Acetabular System and the ASR Hip Resurfacing System. The recall took place in August of 2010, after the FDA had received incident reports regarding the DePuy metal-on-metal hip implants for over two years. Approximately one in eight patients—and possibly more—will require a hip revision s
|
|
Full Story
|
|
|
|